Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Iron pills may boost vaccine power in pregnancy, study hints

NCT ID NCT05385042

Knowledge-focused Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether iron supplements improve how well vaccines work in pregnant women with anemia (low iron). Researchers compared their immune responses to tetanus, diphtheria, and COVID-19 vaccines against women without anemia. The goal was to see if correcting iron deficiency leads to stronger protection for both mother and baby.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

171 people

The number who actually took part.

Started

Jun 2022

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Viable singleton pregnancy\<28 weeks confirmed by ultrasound 2. 18 years and older 3. Willingness and ability to comply with the study protocol for the duration of the study 4. Can understand information about the study and provide consent Exclusion Criteria: 1. Any diphtheria-tetanus vaccine within the previous 2 years 2. History of allergic reaction to diphtheria-tetanus or COVID-19 vaccine 3. Haematocrit \<21% or Haematocrit \>50% 4. Known severe haemoglobinopathy (HbE/beta-thalassaemia syndrome, beta-thalassaemia major or HbH syndrome)\* or G6PD deficiency \* Iron supplementation is safe in pregnant women with haemoglobin E, alpha-thalassemia 1, or beta-thalassemia carriers. 5. HIV-positive 6. Slide confirmed presence of malaria 7. Fever (defined at \>37.5°C) 8. Symptoms of COVID (these women will be PCR tested as routine in clinic) 9. Known severe medical or obstetric complication e.g. valvular heart disease, placenta praevia 10. Known or clinical vitB12 deficiency as indicated by megaloblastic anaemia (pernicious anaemia or clinical symptoms)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia pregnancy disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pregnancy related

Contacts and locations

Locations

  • Shoklo Malaria Research Unit (SMRU)

    Mae Sot, Changwat Tak, 63110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.